S-oxprenolol (ACM-002) / Actimed Therap, Faraday Pharma - LARVOL DELTA

Oxprenolol and metoprolol for prolonged spinal block in rats (ASA 2024) - "Beta-blockers (oxprenolol, metoprolol, acebutolol, and sotalol) were administered intrathecally...The rank order of potency (ED50) for nociceptive blockade was oxprenolol (0.45 [0.41 - 0.49]) = ropivacaine (0.38 [0.33 - 0.42]) > metoprolol (2.82 [2.55 - 3.11]) (P < 0.01)...The duration of action of oxprenolol and metoprolol is similar to ropivacaine at every equipotent dose (ED75, ED50, and ED25). Oxprenolol and metoprolol, as well as ropivacaine, showed a duration of nociceptive block much greater than the motor block."

Preclinical • Anesthesia

Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) - "Actimed Therapeutics Ltd...announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to S-oxprenolol (ACM-002) for the treatment of amyotrophic lateral sclerosis (ALS)...In pre-clinical ALS models, S-oxprenolol has demonstrated significant benefits including slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection, reduction in loss of body mass and improvements in lean body mass."

Orphan drug • Amyotrophic Lateral Sclerosis • CNS Disorders

The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model. (PubMed, J Cachexia Sarcopenia Muscle) - "S-oxprenolol is superior to R-oxprenolol in cancer cachexia animal models and shows promise for a human application in cancer cachexia."

Journal • Preclinical • Cachexia • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Solid Tumor • AMPK • IGF1 • SLC2A1

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol (PRNewswire) - “Actimed Therapeutics…announced a license agreement for S-oxprenolol to Faraday Pharmaceuticals…Under the terms of the agreement, Actimed will receive an upfront payment of $550,000 in equity investment and cash and is also eligible to receive a near-term milestone payment of $2.7m and up to $123.5m in total potential milestone payments. Actimed is also eligible to receive royalties on any future sales of S-oxprenolol. Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS). Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting can impact survival.”

Licensing / partnership • Cachexia • Oncology

Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité - Universitätsmedizin Berlin (PRNewswire) - “Actimed Therapeutics…announces that it has licensed additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis (ALS) from Charité – Universitätsmedizin Berlin (Charité). This gives Actimed global rights in this indication.”

Patent • Amyotrophic Lateral Sclerosis • CNS Disorders